Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective as adjunct therapy for treatment of a wide variety of neoplasms in humans and animals. Previous studies have shown that COX-2 inhibitors can reduce angiogenesis and tumor size. We treated immunodeficient mice implanted with a canine prostate carcinoma xenograft with a selective cyclooxygenase inhibitor, deracoxib, to determine its effects on tumor growth and proliferation.
展开▼
